Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial | Zendy

Meera Gurumurthy | Zendy; Rupangi Verma | Zendy; Claire M. Naftalin | Zendy; KimHor Hee | Zendy; Qingshu Lu | Zendy; Kin Hup Tan | Zendy; Simi Issac | Zendy; Wenwei Lin | Zendy; Angelia Tan | Zendy; KokYong Seng | Zendy; Lawrence Soon-U Lee | Zendy; Nicholas I. Paton | Zendy

Open Access

Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial

Author(s) -

Meera Gurumurthy,

Rupangi Verma,

Claire M. Naftalin,

KimHor Hee,

Qingshu Lu,

Kin Hup Tan,

Simi Issac,

Wenwei Lin,

Angelia Tan,

KokYong Seng,

Lawrence Soon-U Lee,

Nicholas I. Paton

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx081

Subject(s) - rifampicin , clavulanic acid , amoxicillin , mycobacterium tuberculosis , antibacterial agent , pharmacology , microbiology and biotechnology , medicine , tuberculosis , antibiotics , biology , pathology

Faropenem has in vitro activity against Mycobacterium tuberculosis (Mtb) and shows synergy with rifampicin. We tested this in a whole-blood bactericidal activity (WBA) trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research